id,indicator_code,spatial_dim_type,iso_code,region_code,time_dim_type,region,dim1type,year,dim1,dim2type,dim2,dim3type,dim3,data_source_dim_type,data_source_dim,value,numeric_value,low,high,comments,date,time_dimension_value,time_dimension_begin,time_dimension_end,country,indicator_name,language,title
93066,SCSUD_MEDDF,COUNTRY,NZL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
155164,SCSUD_MEDDF,COUNTRY,DMA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
186182,SCSUD_MEDDF,COUNTRY,BLZ,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
175616,SCSUD_MEDDF,COUNTRY,ARM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
146852,SCSUD_MEDDF,COUNTRY,BRA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
146188,SCSUD_MEDDF,COUNTRY,CYP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
122025,SCSUD_MEDDF,COUNTRY,SWZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
249422,SCSUD_MEDDF,COUNTRY,SMR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
114066,SCSUD_MEDDF,COUNTRY,IRL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
276142,SCSUD_MEDDF,COUNTRY,CHE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
95559,SCSUD_MEDDF,COUNTRY,CRI,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
294291,SCSUD_MEDDF,COUNTRY,EST,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
85477,SCSUD_MEDDF,COUNTRY,DOM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
59605,SCSUD_MEDDF,COUNTRY,GEO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
56361,SCSUD_MEDDF,COUNTRY,KOR,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
27349,SCSUD_MEDDF,COUNTRY,TUR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,TÃ¼rkiye,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
23939,SCSUD_MEDDF,COUNTRY,IND,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
337550,SCSUD_MEDDF,COUNTRY,EGY,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
171099,SCSUD_MEDDF,COUNTRY,COL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
343365,SCSUD_MEDDF,COUNTRY,MLT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
173897,SCSUD_MEDDF,COUNTRY,TKM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
392370,SCSUD_MEDDF,COUNTRY,COK,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
361809,SCSUD_MEDDF,COUNTRY,ETH,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
338363,SCSUD_MEDDF,COUNTRY,COL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
219716,SCSUD_MEDDF,COUNTRY,BEL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
219865,SCSUD_MEDDF,COUNTRY,BOL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
221537,SCSUD_MEDDF,COUNTRY,TON,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
455327,SCSUD_MEDDF,COUNTRY,CHN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
393457,SCSUD_MEDDF,COUNTRY,CYP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
269226,SCSUD_MEDDF,COUNTRY,CAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
279803,SCSUD_MEDDF,COUNTRY,FIN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
487431,SCSUD_MEDDF,COUNTRY,PAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
280035,SCSUD_MEDDF,COUNTRY,LVA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
303321,SCSUD_MEDDF,COUNTRY,JPN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
308069,SCSUD_MEDDF,COUNTRY,SSD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
314727,SCSUD_MEDDF,COUNTRY,PRY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
334988,SCSUD_MEDDF,COUNTRY,BHR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
337681,SCSUD_MEDDF,COUNTRY,NGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
394860,SCSUD_MEDDF,COUNTRY,BRA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
602296,SCSUD_MEDDF,COUNTRY,GHA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
428108,SCSUD_MEDDF,COUNTRY,SMR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
437210,SCSUD_MEDDF,COUNTRY,CHL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
151228,SCSUD_MEDDF,COUNTRY,SYR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
448419,SCSUD_MEDDF,COUNTRY,GBR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
571969,SCSUD_MEDDF,COUNTRY,ZAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
641568,SCSUD_MEDDF,COUNTRY,BEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
514348,SCSUD_MEDDF,COUNTRY,HND,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
522089,SCSUD_MEDDF,COUNTRY,EGY,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
524652,SCSUD_MEDDF,COUNTRY,NPL,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
537659,SCSUD_MEDDF,COUNTRY,SMR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
541294,SCSUD_MEDDF,COUNTRY,SYC,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
561397,SCSUD_MEDDF,COUNTRY,AZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
480175,SCSUD_MEDDF,COUNTRY,JAM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
738796,SCSUD_MEDDF,COUNTRY,THA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
505953,SCSUD_MEDDF,COUNTRY,QAT,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
604290,SCSUD_MEDDF,COUNTRY,LCA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
758843,SCSUD_MEDDF,COUNTRY,TUR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,TÃ¼rkiye,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
404289,SCSUD_MEDDF,COUNTRY,ECU,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
609120,SCSUD_MEDDF,COUNTRY,NOR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
815913,SCSUD_MEDDF,COUNTRY,SYR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
609300,SCSUD_MEDDF,COUNTRY,BDI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
841827,SCSUD_MEDDF,COUNTRY,MDA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
452612,SCSUD_MEDDF,COUNTRY,SWE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
867932,SCSUD_MEDDF,COUNTRY,TCD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
884393,SCSUD_MEDDF,COUNTRY,BEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
693798,SCSUD_MEDDF,COUNTRY,SWZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
700756,SCSUD_MEDDF,COUNTRY,DEU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
734424,SCSUD_MEDDF,COUNTRY,IND,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
674918,SCSUD_MEDDF,COUNTRY,PHL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
799004,SCSUD_MEDDF,COUNTRY,ITA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
630711,SCSUD_MEDDF,COUNTRY,ZMB,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
855019,SCSUD_MEDDF,COUNTRY,ITA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
727296,SCSUD_MEDDF,COUNTRY,MCO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
822762,SCSUD_MEDDF,COUNTRY,COD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
661301,SCSUD_MEDDF,COUNTRY,BRB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1064598,SCSUD_MEDDF,COUNTRY,GRC,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
928323,SCSUD_MEDDF,COUNTRY,GHA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
804447,SCSUD_MEDDF,COUNTRY,OMN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1113668,SCSUD_MEDDF,COUNTRY,SWE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
890806,SCSUD_MEDDF,COUNTRY,HUN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
988606,SCSUD_MEDDF,COUNTRY,MNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
932774,SCSUD_MEDDF,COUNTRY,CZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1028266,SCSUD_MEDDF,COUNTRY,VNM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
888167,SCSUD_MEDDF,COUNTRY,JPN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1044296,SCSUD_MEDDF,COUNTRY,ISR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1214936,SCSUD_MEDDF,COUNTRY,BLR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1040373,SCSUD_MEDDF,COUNTRY,TCD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
986014,SCSUD_MEDDF,COUNTRY,JOR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
888719,SCSUD_MEDDF,COUNTRY,SRB,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1272228,SCSUD_MEDDF,COUNTRY,LBR,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
980293,SCSUD_MEDDF,COUNTRY,RUS,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1019760,SCSUD_MEDDF,COUNTRY,IND,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1284962,SCSUD_MEDDF,COUNTRY,LCA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1069550,SCSUD_MEDDF,COUNTRY,QAT,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1189896,SCSUD_MEDDF,COUNTRY,SWZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1208040,SCSUD_MEDDF,COUNTRY,DOM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1121111,SCSUD_MEDDF,COUNTRY,FRA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1334706,SCSUD_MEDDF,COUNTRY,SLE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1340938,SCSUD_MEDDF,COUNTRY,KGZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1052668,SCSUD_MEDDF,COUNTRY,GHA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1256110,SCSUD_MEDDF,COUNTRY,ECU,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
979752,SCSUD_MEDDF,COUNTRY,MLI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1209875,SCSUD_MEDDF,COUNTRY,GRC,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1283813,SCSUD_MEDDF,COUNTRY,BWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1283970,SCSUD_MEDDF,COUNTRY,SEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1321926,SCSUD_MEDDF,COUNTRY,SVK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1469605,SCSUD_MEDDF,COUNTRY,COK,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1477059,SCSUD_MEDDF,COUNTRY,MMR,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1327434,SCSUD_MEDDF,COUNTRY,BGD,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1117974,SCSUD_MEDDF,COUNTRY,ETH,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1296776,SCSUD_MEDDF,COUNTRY,KHM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1363158,SCSUD_MEDDF,COUNTRY,AUT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1558437,SCSUD_MEDDF,COUNTRY,LVA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1365535,SCSUD_MEDDF,COUNTRY,BRA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1370625,SCSUD_MEDDF,COUNTRY,AGO,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1576902,SCSUD_MEDDF,COUNTRY,AUS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1577223,SCSUD_MEDDF,COUNTRY,HUN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1220714,SCSUD_MEDDF,COUNTRY,POL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1387481,SCSUD_MEDDF,COUNTRY,NPL,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1316126,SCSUD_MEDDF,COUNTRY,PHL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1591128,SCSUD_MEDDF,COUNTRY,ISL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1150268,SCSUD_MEDDF,COUNTRY,COK,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1491158,SCSUD_MEDDF,COUNTRY,DNK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1397883,SCSUD_MEDDF,COUNTRY,PHL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1520674,SCSUD_MEDDF,COUNTRY,HND,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1543251,SCSUD_MEDDF,COUNTRY,ZWE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1555952,SCSUD_MEDDF,COUNTRY,AUS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1650678,SCSUD_MEDDF,COUNTRY,IDN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1667368,SCSUD_MEDDF,COUNTRY,THA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1570851,SCSUD_MEDDF,COUNTRY,ISL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1589827,SCSUD_MEDDF,COUNTRY,SLV,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1590105,SCSUD_MEDDF,COUNTRY,LUX,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1405964,SCSUD_MEDDF,COUNTRY,BOL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1497474,SCSUD_MEDDF,COUNTRY,PER,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1498328,SCSUD_MEDDF,COUNTRY,UGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1643527,SCSUD_MEDDF,COUNTRY,MCO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1647403,SCSUD_MEDDF,COUNTRY,LKA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1654611,SCSUD_MEDDF,COUNTRY,SWZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1683571,SCSUD_MEDDF,COUNTRY,BEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1788975,SCSUD_MEDDF,COUNTRY,NIC,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1701953,SCSUD_MEDDF,COUNTRY,LBR,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1578039,SCSUD_MEDDF,COUNTRY,LBR,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1803347,SCSUD_MEDDF,COUNTRY,SOM,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1707050,SCSUD_MEDDF,COUNTRY,SLV,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1618262,SCSUD_MEDDF,COUNTRY,LCA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1861371,SCSUD_MEDDF,COUNTRY,GRD,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1715577,SCSUD_MEDDF,COUNTRY,BEL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1627710,SCSUD_MEDDF,COUNTRY,CAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1866514,SCSUD_MEDDF,COUNTRY,ROU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1605890,SCSUD_MEDDF,COUNTRY,VUT,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1636229,SCSUD_MEDDF,COUNTRY,MKD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1456711,SCSUD_MEDDF,COUNTRY,TUR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,TÃ¼rkiye,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1904265,SCSUD_MEDDF,COUNTRY,PRT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1600029,SCSUD_MEDDF,COUNTRY,IRL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1918938,SCSUD_MEDDF,COUNTRY,ZWE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1753970,SCSUD_MEDDF,COUNTRY,KGZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1928422,SCSUD_MEDDF,COUNTRY,DMA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1765377,SCSUD_MEDDF,COUNTRY,CHN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1798536,SCSUD_MEDDF,COUNTRY,IRL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1821085,SCSUD_MEDDF,COUNTRY,CAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1801781,SCSUD_MEDDF,COUNTRY,ETH,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1954599,SCSUD_MEDDF,COUNTRY,LBR,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1860672,SCSUD_MEDDF,COUNTRY,IDN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2006960,SCSUD_MEDDF,COUNTRY,MLI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1926390,SCSUD_MEDDF,COUNTRY,CYP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1930804,SCSUD_MEDDF,COUNTRY,MAR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1759571,SCSUD_MEDDF,COUNTRY,ZMB,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1789930,SCSUD_MEDDF,COUNTRY,PNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1941584,SCSUD_MEDDF,COUNTRY,AND,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2009086,SCSUD_MEDDF,COUNTRY,COD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2095311,SCSUD_MEDDF,COUNTRY,TON,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1861567,SCSUD_MEDDF,COUNTRY,NIC,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1864411,SCSUD_MEDDF,COUNTRY,SLE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1915355,SCSUD_MEDDF,COUNTRY,FIN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2028016,SCSUD_MEDDF,COUNTRY,COL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2047144,SCSUD_MEDDF,COUNTRY,NGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1940423,SCSUD_MEDDF,COUNTRY,NPL,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2025670,SCSUD_MEDDF,COUNTRY,FIN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2074977,SCSUD_MEDDF,COUNTRY,TKM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2217857,SCSUD_MEDDF,COUNTRY,SVN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2080999,SCSUD_MEDDF,COUNTRY,LKA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2242898,SCSUD_MEDDF,COUNTRY,CHN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2005064,SCSUD_MEDDF,COUNTRY,BRB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1892127,SCSUD_MEDDF,COUNTRY,BDI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
1894773,SCSUD_MEDDF,COUNTRY,MYS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2141282,SCSUD_MEDDF,COUNTRY,PER,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2162893,SCSUD_MEDDF,COUNTRY,ISR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2199558,SCSUD_MEDDF,COUNTRY,ARM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2089864,SCSUD_MEDDF,COUNTRY,ECU,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2090119,SCSUD_MEDDF,COUNTRY,SRB,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2091640,SCSUD_MEDDF,COUNTRY,SVN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2112655,SCSUD_MEDDF,COUNTRY,AUS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2291397,SCSUD_MEDDF,COUNTRY,PAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2306779,SCSUD_MEDDF,COUNTRY,ESP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2127024,SCSUD_MEDDF,COUNTRY,ZAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2134351,SCSUD_MEDDF,COUNTRY,MKD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2481715,SCSUD_MEDDF,COUNTRY,AUT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2158625,SCSUD_MEDDF,COUNTRY,HUN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2197190,SCSUD_MEDDF,COUNTRY,CZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2264273,SCSUD_MEDDF,COUNTRY,SEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2269258,SCSUD_MEDDF,COUNTRY,ZAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2269735,SCSUD_MEDDF,COUNTRY,CAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2529794,SCSUD_MEDDF,COUNTRY,ISR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2270604,SCSUD_MEDDF,COUNTRY,ZWE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2274149,SCSUD_MEDDF,COUNTRY,CHL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2282633,SCSUD_MEDDF,COUNTRY,BWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2310418,SCSUD_MEDDF,COUNTRY,CYP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2506330,SCSUD_MEDDF,COUNTRY,KHM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2326068,SCSUD_MEDDF,COUNTRY,BLZ,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2513223,SCSUD_MEDDF,COUNTRY,BEL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2345750,SCSUD_MEDDF,COUNTRY,MEX,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2354240,SCSUD_MEDDF,COUNTRY,ETH,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2608846,SCSUD_MEDDF,COUNTRY,COG,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2527811,SCSUD_MEDDF,COUNTRY,AFG,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2267512,SCSUD_MEDDF,COUNTRY,GEO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2614554,SCSUD_MEDDF,COUNTRY,SAU,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2377219,SCSUD_MEDDF,COUNTRY,JAM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2418697,SCSUD_MEDDF,COUNTRY,AGO,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2528498,SCSUD_MEDDF,COUNTRY,VUT,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2419117,SCSUD_MEDDF,COUNTRY,JAM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2536306,SCSUD_MEDDF,COUNTRY,MYS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2537621,SCSUD_MEDDF,COUNTRY,KHM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2448187,SCSUD_MEDDF,COUNTRY,MEX,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2556857,SCSUD_MEDDF,COUNTRY,FRA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2548319,SCSUD_MEDDF,COUNTRY,TZA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2720077,SCSUD_MEDDF,COUNTRY,POL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2562837,SCSUD_MEDDF,COUNTRY,GBR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2575640,SCSUD_MEDDF,COUNTRY,RWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2589813,SCSUD_MEDDF,COUNTRY,KAZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2641253,SCSUD_MEDDF,COUNTRY,COG,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2641938,SCSUD_MEDDF,COUNTRY,PER,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2688017,SCSUD_MEDDF,COUNTRY,CIV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2721232,SCSUD_MEDDF,COUNTRY,IRL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2698700,SCSUD_MEDDF,COUNTRY,HRV,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2710679,SCSUD_MEDDF,COUNTRY,SSD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2716417,SCSUD_MEDDF,COUNTRY,SDN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2721531,SCSUD_MEDDF,COUNTRY,MOZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2848965,SCSUD_MEDDF,COUNTRY,SAU,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2731463,SCSUD_MEDDF,COUNTRY,BHR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2731578,SCSUD_MEDDF,COUNTRY,SLE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2740703,SCSUD_MEDDF,COUNTRY,BRB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2891331,SCSUD_MEDDF,COUNTRY,BWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2755335,SCSUD_MEDDF,COUNTRY,LUX,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2611491,SCSUD_MEDDF,COUNTRY,AZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2772036,SCSUD_MEDDF,COUNTRY,BLR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2779626,SCSUD_MEDDF,COUNTRY,TUR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,TÃ¼rkiye,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2780296,SCSUD_MEDDF,COUNTRY,GRD,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2675514,SCSUD_MEDDF,COUNTRY,IND,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2799026,SCSUD_MEDDF,COUNTRY,LKA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2800479,SCSUD_MEDDF,COUNTRY,TUN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2803395,SCSUD_MEDDF,COUNTRY,SEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2807408,SCSUD_MEDDF,COUNTRY,GUY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2823953,SCSUD_MEDDF,COUNTRY,IRN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2880275,SCSUD_MEDDF,COUNTRY,IND,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2898852,SCSUD_MEDDF,COUNTRY,NOR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2920935,SCSUD_MEDDF,COUNTRY,ITA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2936398,SCSUD_MEDDF,COUNTRY,CHE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2953611,SCSUD_MEDDF,COUNTRY,MNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2977725,SCSUD_MEDDF,COUNTRY,LUX,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3029092,SCSUD_MEDDF,COUNTRY,MLI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3095366,SCSUD_MEDDF,COUNTRY,KOR,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2826363,SCSUD_MEDDF,COUNTRY,DMA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3120712,SCSUD_MEDDF,COUNTRY,MOZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3125284,SCSUD_MEDDF,COUNTRY,KNA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3130794,SCSUD_MEDDF,COUNTRY,KHM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3131597,SCSUD_MEDDF,COUNTRY,CHL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3135024,SCSUD_MEDDF,COUNTRY,MMR,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3154964,SCSUD_MEDDF,COUNTRY,MAR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3158203,SCSUD_MEDDF,COUNTRY,NZL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3164319,SCSUD_MEDDF,COUNTRY,ECU,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3165760,SCSUD_MEDDF,COUNTRY,KEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3166373,SCSUD_MEDDF,COUNTRY,ITA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3177902,SCSUD_MEDDF,COUNTRY,GRC,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3051973,SCSUD_MEDDF,COUNTRY,UGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3072307,SCSUD_MEDDF,COUNTRY,VCT,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3349774,SCSUD_MEDDF,COUNTRY,NOR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3358913,SCSUD_MEDDF,COUNTRY,LVA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3364373,SCSUD_MEDDF,COUNTRY,BEL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3188365,SCSUD_MEDDF,COUNTRY,MLT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3379193,SCSUD_MEDDF,COUNTRY,PRT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
2839158,SCSUD_MEDDF,COUNTRY,GBR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3202264,SCSUD_MEDDF,COUNTRY,GRD,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3388711,SCSUD_MEDDF,COUNTRY,CYP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3400511,SCSUD_MEDDF,COUNTRY,KAZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3227985,SCSUD_MEDDF,COUNTRY,TON,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3244636,SCSUD_MEDDF,COUNTRY,BGD,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3411263,SCSUD_MEDDF,COUNTRY,TJK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3250163,SCSUD_MEDDF,COUNTRY,HND,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3262683,SCSUD_MEDDF,COUNTRY,NGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3419102,SCSUD_MEDDF,COUNTRY,MLT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3324650,SCSUD_MEDDF,COUNTRY,KGZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3445264,SCSUD_MEDDF,COUNTRY,MLI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3329370,SCSUD_MEDDF,COUNTRY,JPN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3347037,SCSUD_MEDDF,COUNTRY,SDN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3199436,SCSUD_MEDDF,COUNTRY,LKA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3482739,SCSUD_MEDDF,COUNTRY,MAR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3518929,SCSUD_MEDDF,COUNTRY,ESP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3383468,SCSUD_MEDDF,COUNTRY,AZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3411001,SCSUD_MEDDF,COUNTRY,EGY,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3209569,SCSUD_MEDDF,COUNTRY,BTN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3220857,SCSUD_MEDDF,COUNTRY,BDI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3411056,SCSUD_MEDDF,COUNTRY,CAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3416150,SCSUD_MEDDF,COUNTRY,DEU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3444177,SCSUD_MEDDF,COUNTRY,KGZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3273351,SCSUD_MEDDF,COUNTRY,AZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3515682,SCSUD_MEDDF,COUNTRY,DMA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3302344,SCSUD_MEDDF,COUNTRY,CPV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3317269,SCSUD_MEDDF,COUNTRY,ITA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3318662,SCSUD_MEDDF,COUNTRY,TCD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3590637,SCSUD_MEDDF,COUNTRY,RUS,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3456832,SCSUD_MEDDF,COUNTRY,AZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3465295,SCSUD_MEDDF,COUNTRY,AGO,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3477795,SCSUD_MEDDF,COUNTRY,NZL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3647449,SCSUD_MEDDF,COUNTRY,TON,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3498936,SCSUD_MEDDF,COUNTRY,SMR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3540317,SCSUD_MEDDF,COUNTRY,MAR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3547815,SCSUD_MEDDF,COUNTRY,SGP,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3561512,SCSUD_MEDDF,COUNTRY,PHL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3583393,SCSUD_MEDDF,COUNTRY,UKR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3588660,SCSUD_MEDDF,COUNTRY,ECU,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3591111,SCSUD_MEDDF,COUNTRY,GRD,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3525552,SCSUD_MEDDF,COUNTRY,HUN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3528091,SCSUD_MEDDF,COUNTRY,SLV,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3552641,SCSUD_MEDDF,COUNTRY,BTN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3626652,SCSUD_MEDDF,COUNTRY,SAU,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3649472,SCSUD_MEDDF,COUNTRY,IRQ,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3539507,SCSUD_MEDDF,COUNTRY,CPV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3668837,SCSUD_MEDDF,COUNTRY,SGP,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3716245,SCSUD_MEDDF,COUNTRY,SAU,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3716292,SCSUD_MEDDF,COUNTRY,MEX,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3669056,SCSUD_MEDDF,COUNTRY,VCT,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3575008,SCSUD_MEDDF,COUNTRY,GUY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3716317,SCSUD_MEDDF,COUNTRY,BRB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3522459,SCSUD_MEDDF,COUNTRY,GHA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3682328,SCSUD_MEDDF,COUNTRY,PNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3720268,SCSUD_MEDDF,COUNTRY,MEX,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3683596,SCSUD_MEDDF,COUNTRY,TZA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3600203,SCSUD_MEDDF,COUNTRY,GTM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3618590,SCSUD_MEDDF,COUNTRY,OMN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3618689,SCSUD_MEDDF,COUNTRY,LCA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3701703,SCSUD_MEDDF,COUNTRY,COD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3704541,SCSUD_MEDDF,COUNTRY,LUX,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3746903,SCSUD_MEDDF,COUNTRY,ROU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3748691,SCSUD_MEDDF,COUNTRY,ISR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3766090,SCSUD_MEDDF,COUNTRY,NIC,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3672465,SCSUD_MEDDF,COUNTRY,SDN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3695175,SCSUD_MEDDF,COUNTRY,LVA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3892665,SCSUD_MEDDF,COUNTRY,DEU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3877990,SCSUD_MEDDF,COUNTRY,CZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3879932,SCSUD_MEDDF,COUNTRY,ATG,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3885560,SCSUD_MEDDF,COUNTRY,VUT,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3886082,SCSUD_MEDDF,COUNTRY,ATG,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3930638,SCSUD_MEDDF,COUNTRY,BWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3771612,SCSUD_MEDDF,COUNTRY,TUN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3887891,SCSUD_MEDDF,COUNTRY,SOM,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3775538,SCSUD_MEDDF,COUNTRY,PRY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3791328,SCSUD_MEDDF,COUNTRY,CRI,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3984111,SCSUD_MEDDF,COUNTRY,MAR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3816753,SCSUD_MEDDF,COUNTRY,FRA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3821665,SCSUD_MEDDF,COUNTRY,SUR,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3900235,SCSUD_MEDDF,COUNTRY,SWZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4077989,SCSUD_MEDDF,COUNTRY,AND,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4079759,SCSUD_MEDDF,COUNTRY,CZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3828834,SCSUD_MEDDF,COUNTRY,URY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4101978,SCSUD_MEDDF,COUNTRY,JAM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3845882,SCSUD_MEDDF,COUNTRY,DMA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3849223,SCSUD_MEDDF,COUNTRY,TZA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4111786,SCSUD_MEDDF,COUNTRY,ATG,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4125847,SCSUD_MEDDF,COUNTRY,CUB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4126545,SCSUD_MEDDF,COUNTRY,CAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4152258,SCSUD_MEDDF,COUNTRY,COG,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3851436,SCSUD_MEDDF,COUNTRY,ISR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3864713,SCSUD_MEDDF,COUNTRY,GEO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4183142,SCSUD_MEDDF,COUNTRY,DNK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3913652,SCSUD_MEDDF,COUNTRY,URY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3915204,SCSUD_MEDDF,COUNTRY,COD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4214423,SCSUD_MEDDF,COUNTRY,FIN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3931272,SCSUD_MEDDF,COUNTRY,KGZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4245346,SCSUD_MEDDF,COUNTRY,AND,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3970727,SCSUD_MEDDF,COUNTRY,COG,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3981676,SCSUD_MEDDF,COUNTRY,BTN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
3993265,SCSUD_MEDDF,COUNTRY,ETH,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4276859,SCSUD_MEDDF,COUNTRY,GTM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4012221,SCSUD_MEDDF,COUNTRY,LVA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4019515,SCSUD_MEDDF,COUNTRY,EST,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4035759,SCSUD_MEDDF,COUNTRY,EGY,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4095760,SCSUD_MEDDF,COUNTRY,MKD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4105023,SCSUD_MEDDF,COUNTRY,OMN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4189681,SCSUD_MEDDF,COUNTRY,CUB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4222877,SCSUD_MEDDF,COUNTRY,NOR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4262892,SCSUD_MEDDF,COUNTRY,FSM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4264830,SCSUD_MEDDF,COUNTRY,CPV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4360180,SCSUD_MEDDF,COUNTRY,JAM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4265759,SCSUD_MEDDF,COUNTRY,QAT,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4278244,SCSUD_MEDDF,COUNTRY,EST,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4283444,SCSUD_MEDDF,COUNTRY,SAU,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4291008,SCSUD_MEDDF,COUNTRY,MCO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4309562,SCSUD_MEDDF,COUNTRY,COL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4111006,SCSUD_MEDDF,COUNTRY,SLV,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4488358,SCSUD_MEDDF,COUNTRY,PRY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4171315,SCSUD_MEDDF,COUNTRY,SLE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4332454,SCSUD_MEDDF,COUNTRY,SOM,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4541062,SCSUD_MEDDF,COUNTRY,MDA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4348962,SCSUD_MEDDF,COUNTRY,NZL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4353920,SCSUD_MEDDF,COUNTRY,CUB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4552908,SCSUD_MEDDF,COUNTRY,CHE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4587443,SCSUD_MEDDF,COUNTRY,DMA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4408540,SCSUD_MEDDF,COUNTRY,VNM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4425525,SCSUD_MEDDF,COUNTRY,BOL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4681194,SCSUD_MEDDF,COUNTRY,HND,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4327307,SCSUD_MEDDF,COUNTRY,NLD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4479913,SCSUD_MEDDF,COUNTRY,CPV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4765841,SCSUD_MEDDF,COUNTRY,COL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4527004,SCSUD_MEDDF,COUNTRY,HND,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4489670,SCSUD_MEDDF,COUNTRY,VUT,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4493262,SCSUD_MEDDF,COUNTRY,MOZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4830571,SCSUD_MEDDF,COUNTRY,SSD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4524448,SCSUD_MEDDF,COUNTRY,CPV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4644746,SCSUD_MEDDF,COUNTRY,URY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4651962,SCSUD_MEDDF,COUNTRY,VCT,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4549391,SCSUD_MEDDF,COUNTRY,ATG,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4600297,SCSUD_MEDDF,COUNTRY,JOR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4775480,SCSUD_MEDDF,COUNTRY,MOZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4544567,SCSUD_MEDDF,COUNTRY,ETH,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4886870,SCSUD_MEDDF,COUNTRY,ARM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4566376,SCSUD_MEDDF,COUNTRY,ZMB,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4891205,SCSUD_MEDDF,COUNTRY,KHM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4609585,SCSUD_MEDDF,COUNTRY,DOM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4886012,SCSUD_MEDDF,COUNTRY,CAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4675366,SCSUD_MEDDF,COUNTRY,CHL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4691911,SCSUD_MEDDF,COUNTRY,BLR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5006208,SCSUD_MEDDF,COUNTRY,PRY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4703600,SCSUD_MEDDF,COUNTRY,MAR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4704233,SCSUD_MEDDF,COUNTRY,UGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4886047,SCSUD_MEDDF,COUNTRY,SRB,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4729213,SCSUD_MEDDF,COUNTRY,SUR,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4779943,SCSUD_MEDDF,COUNTRY,KAZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4786149,SCSUD_MEDDF,COUNTRY,BFA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4786503,SCSUD_MEDDF,COUNTRY,AFG,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5093679,SCSUD_MEDDF,COUNTRY,ESP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5102142,SCSUD_MEDDF,COUNTRY,SYC,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4931729,SCSUD_MEDDF,COUNTRY,PNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4932936,SCSUD_MEDDF,COUNTRY,LTU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4937219,SCSUD_MEDDF,COUNTRY,PRY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4952936,SCSUD_MEDDF,COUNTRY,VCT,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4954323,SCSUD_MEDDF,COUNTRY,AUS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4963126,SCSUD_MEDDF,COUNTRY,SMR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4989204,SCSUD_MEDDF,COUNTRY,HRV,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4995568,SCSUD_MEDDF,COUNTRY,MOZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5029786,SCSUD_MEDDF,COUNTRY,KNA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5188735,SCSUD_MEDDF,COUNTRY,BEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5094360,SCSUD_MEDDF,COUNTRY,PER,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4981391,SCSUD_MEDDF,COUNTRY,RWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4992645,SCSUD_MEDDF,COUNTRY,POL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4997559,SCSUD_MEDDF,COUNTRY,EGY,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5038773,SCSUD_MEDDF,COUNTRY,GRD,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5243467,SCSUD_MEDDF,COUNTRY,CHL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5252415,SCSUD_MEDDF,COUNTRY,MKD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5060382,SCSUD_MEDDF,COUNTRY,TKM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5278891,SCSUD_MEDDF,COUNTRY,SYC,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5292307,SCSUD_MEDDF,COUNTRY,LBR,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5296827,SCSUD_MEDDF,COUNTRY,ZMB,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5110337,SCSUD_MEDDF,COUNTRY,CHN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5136775,SCSUD_MEDDF,COUNTRY,AND,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5138099,SCSUD_MEDDF,COUNTRY,CAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5197844,SCSUD_MEDDF,COUNTRY,SVK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5154001,SCSUD_MEDDF,COUNTRY,GHA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5372583,SCSUD_MEDDF,COUNTRY,BTN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5386022,SCSUD_MEDDF,COUNTRY,TJK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
4988910,SCSUD_MEDDF,COUNTRY,CZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5176545,SCSUD_MEDDF,COUNTRY,ESP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5180106,SCSUD_MEDDF,COUNTRY,NZL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5216831,SCSUD_MEDDF,COUNTRY,ROU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5229787,SCSUD_MEDDF,COUNTRY,MMR,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5185611,SCSUD_MEDDF,COUNTRY,MMR,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5510544,SCSUD_MEDDF,COUNTRY,JPN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5192973,SCSUD_MEDDF,COUNTRY,TCD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5302456,SCSUD_MEDDF,COUNTRY,NGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5561524,SCSUD_MEDDF,COUNTRY,SYR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5319236,SCSUD_MEDDF,COUNTRY,BLR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5374956,SCSUD_MEDDF,COUNTRY,BWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5391231,SCSUD_MEDDF,COUNTRY,ZAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5400244,SCSUD_MEDDF,COUNTRY,PAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5450382,SCSUD_MEDDF,COUNTRY,SUR,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5491127,SCSUD_MEDDF,COUNTRY,DNK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5500077,SCSUD_MEDDF,COUNTRY,BTN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5503369,SCSUD_MEDDF,COUNTRY,KOR,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5644747,SCSUD_MEDDF,COUNTRY,RWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5645575,SCSUD_MEDDF,COUNTRY,KNA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5562364,SCSUD_MEDDF,COUNTRY,SYC,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5656712,SCSUD_MEDDF,COUNTRY,LTU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5675552,SCSUD_MEDDF,COUNTRY,CIV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5581593,SCSUD_MEDDF,COUNTRY,SGP,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5338318,SCSUD_MEDDF,COUNTRY,FIN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5354003,SCSUD_MEDDF,COUNTRY,KAZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5598694,SCSUD_MEDDF,COUNTRY,CHE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5624529,SCSUD_MEDDF,COUNTRY,MYS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5493530,SCSUD_MEDDF,COUNTRY,SYR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5635533,SCSUD_MEDDF,COUNTRY,MEX,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5747683,SCSUD_MEDDF,COUNTRY,NZL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5778523,SCSUD_MEDDF,COUNTRY,BHR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5781385,SCSUD_MEDDF,COUNTRY,AUT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5534132,SCSUD_MEDDF,COUNTRY,ISR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5655062,SCSUD_MEDDF,COUNTRY,BLZ,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5657345,SCSUD_MEDDF,COUNTRY,ITA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5798663,SCSUD_MEDDF,COUNTRY,BWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5691494,SCSUD_MEDDF,COUNTRY,BFA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5813970,SCSUD_MEDDF,COUNTRY,SUR,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5700223,SCSUD_MEDDF,COUNTRY,BRA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5704865,SCSUD_MEDDF,COUNTRY,GUY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5707264,SCSUD_MEDDF,COUNTRY,QAT,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5650833,SCSUD_MEDDF,COUNTRY,AND,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5655170,SCSUD_MEDDF,COUNTRY,VUT,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5685695,SCSUD_MEDDF,COUNTRY,KOR,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5736573,SCSUD_MEDDF,COUNTRY,IRQ,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5652684,SCSUD_MEDDF,COUNTRY,PAK,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5885852,SCSUD_MEDDF,COUNTRY,SGP,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5914992,SCSUD_MEDDF,COUNTRY,BRB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5812868,SCSUD_MEDDF,COUNTRY,NLD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5934002,SCSUD_MEDDF,COUNTRY,NOR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5815481,SCSUD_MEDDF,COUNTRY,CUB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5829993,SCSUD_MEDDF,COUNTRY,SRB,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5970192,SCSUD_MEDDF,COUNTRY,TJK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5834933,SCSUD_MEDDF,COUNTRY,MCO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5976229,SCSUD_MEDDF,COUNTRY,FSM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5835610,SCSUD_MEDDF,COUNTRY,MDA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5991855,SCSUD_MEDDF,COUNTRY,CYP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5847044,SCSUD_MEDDF,COUNTRY,OMN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5878657,SCSUD_MEDDF,COUNTRY,SVN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5756209,SCSUD_MEDDF,COUNTRY,SVK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6077720,SCSUD_MEDDF,COUNTRY,SGP,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5783420,SCSUD_MEDDF,COUNTRY,MLT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6115441,SCSUD_MEDDF,COUNTRY,SEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6119344,SCSUD_MEDDF,COUNTRY,GBR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5911201,SCSUD_MEDDF,COUNTRY,SOM,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5916043,SCSUD_MEDDF,COUNTRY,ZMB,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5986434,SCSUD_MEDDF,COUNTRY,FRA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5990673,SCSUD_MEDDF,COUNTRY,DNK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5994876,SCSUD_MEDDF,COUNTRY,QAT,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
5994963,SCSUD_MEDDF,COUNTRY,LBR,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6023932,SCSUD_MEDDF,COUNTRY,URY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6027950,SCSUD_MEDDF,COUNTRY,IRQ,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6095088,SCSUD_MEDDF,COUNTRY,UKR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6135535,SCSUD_MEDDF,COUNTRY,CZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6167682,SCSUD_MEDDF,COUNTRY,MLI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6127002,SCSUD_MEDDF,COUNTRY,ZAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6178244,SCSUD_MEDDF,COUNTRY,SDN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6185282,SCSUD_MEDDF,COUNTRY,TZA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6281462,SCSUD_MEDDF,COUNTRY,AUT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6188340,SCSUD_MEDDF,COUNTRY,VNM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6285752,SCSUD_MEDDF,COUNTRY,SYR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6190476,SCSUD_MEDDF,COUNTRY,MYS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6198114,SCSUD_MEDDF,COUNTRY,KOR,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6001794,SCSUD_MEDDF,COUNTRY,PER,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6105882,SCSUD_MEDDF,COUNTRY,BFA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6086435,SCSUD_MEDDF,COUNTRY,EGY,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6089700,SCSUD_MEDDF,COUNTRY,FSM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6097383,SCSUD_MEDDF,COUNTRY,CRI,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6381270,SCSUD_MEDDF,COUNTRY,JOR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6199376,SCSUD_MEDDF,COUNTRY,ZWE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6415384,SCSUD_MEDDF,COUNTRY,CHL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6248629,SCSUD_MEDDF,COUNTRY,URY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6250954,SCSUD_MEDDF,COUNTRY,GTM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6275420,SCSUD_MEDDF,COUNTRY,BHR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6279711,SCSUD_MEDDF,COUNTRY,JOR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6283526,SCSUD_MEDDF,COUNTRY,MYS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6303671,SCSUD_MEDDF,COUNTRY,PNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6334814,SCSUD_MEDDF,COUNTRY,BHR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6338730,SCSUD_MEDDF,COUNTRY,CIV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6393221,SCSUD_MEDDF,COUNTRY,DEU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6395548,SCSUD_MEDDF,COUNTRY,LTU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6359107,SCSUD_MEDDF,COUNTRY,FSM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6360413,SCSUD_MEDDF,COUNTRY,NIC,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6207639,SCSUD_MEDDF,COUNTRY,QAT,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6218098,SCSUD_MEDDF,COUNTRY,BOL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6404006,SCSUD_MEDDF,COUNTRY,BEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6361239,SCSUD_MEDDF,COUNTRY,KGZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6366552,SCSUD_MEDDF,COUNTRY,SWE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6367251,SCSUD_MEDDF,COUNTRY,MMR,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6383114,SCSUD_MEDDF,COUNTRY,AUT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6419709,SCSUD_MEDDF,COUNTRY,SEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6456706,SCSUD_MEDDF,COUNTRY,SYR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6664597,SCSUD_MEDDF,COUNTRY,ECU,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6472776,SCSUD_MEDDF,COUNTRY,BFA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6533114,SCSUD_MEDDF,COUNTRY,SDN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6689678,SCSUD_MEDDF,COUNTRY,JPN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6536339,SCSUD_MEDDF,COUNTRY,SWE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6368470,SCSUD_MEDDF,COUNTRY,UGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6646864,SCSUD_MEDDF,COUNTRY,NGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6649535,SCSUD_MEDDF,COUNTRY,ESP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6665036,SCSUD_MEDDF,COUNTRY,MNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6755452,SCSUD_MEDDF,COUNTRY,SRB,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6669490,SCSUD_MEDDF,COUNTRY,THA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6683490,SCSUD_MEDDF,COUNTRY,SUR,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6695231,SCSUD_MEDDF,COUNTRY,CIV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6697227,SCSUD_MEDDF,COUNTRY,BEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6563061,SCSUD_MEDDF,COUNTRY,ISL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6568659,SCSUD_MEDDF,COUNTRY,BFA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6872473,SCSUD_MEDDF,COUNTRY,SVK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6882026,SCSUD_MEDDF,COUNTRY,GRC,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6618122,SCSUD_MEDDF,COUNTRY,ROU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6899193,SCSUD_MEDDF,COUNTRY,TUN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6626886,SCSUD_MEDDF,COUNTRY,IRQ,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6637728,SCSUD_MEDDF,COUNTRY,PAK,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6721929,SCSUD_MEDDF,COUNTRY,CIV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6924417,SCSUD_MEDDF,COUNTRY,BLZ,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6732185,SCSUD_MEDDF,COUNTRY,GBR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6743106,SCSUD_MEDDF,COUNTRY,EST,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6783126,SCSUD_MEDDF,COUNTRY,MKD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6790346,SCSUD_MEDDF,COUNTRY,LTU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6808309,SCSUD_MEDDF,COUNTRY,JOR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6827299,SCSUD_MEDDF,COUNTRY,GUY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6999664,SCSUD_MEDDF,COUNTRY,POL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6828828,SCSUD_MEDDF,COUNTRY,BGD,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6835850,SCSUD_MEDDF,COUNTRY,MCO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6841930,SCSUD_MEDDF,COUNTRY,BTN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6853469,SCSUD_MEDDF,COUNTRY,MMR,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6866202,SCSUD_MEDDF,COUNTRY,GUY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6607617,SCSUD_MEDDF,COUNTRY,IRN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6896063,SCSUD_MEDDF,COUNTRY,PHL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7068725,SCSUD_MEDDF,COUNTRY,IRL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6638733,SCSUD_MEDDF,COUNTRY,GTM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6644580,SCSUD_MEDDF,COUNTRY,LCA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6931787,SCSUD_MEDDF,COUNTRY,HRV,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6947086,SCSUD_MEDDF,COUNTRY,COG,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6925009,SCSUD_MEDDF,COUNTRY,ZWE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6965037,SCSUD_MEDDF,COUNTRY,IRN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6979056,SCSUD_MEDDF,COUNTRY,ARM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
6981063,SCSUD_MEDDF,COUNTRY,COD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7157758,SCSUD_MEDDF,COUNTRY,TUR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,TÃ¼rkiye,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7049946,SCSUD_MEDDF,COUNTRY,BEL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7069201,SCSUD_MEDDF,COUNTRY,BEL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7002178,SCSUD_MEDDF,COUNTRY,KNA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7088058,SCSUD_MEDDF,COUNTRY,ISL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7237622,SCSUD_MEDDF,COUNTRY,NPL,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7092355,SCSUD_MEDDF,COUNTRY,MNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7097577,SCSUD_MEDDF,COUNTRY,MLT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7142653,SCSUD_MEDDF,COUNTRY,FRA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7115130,SCSUD_MEDDF,COUNTRY,CRI,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7146686,SCSUD_MEDDF,COUNTRY,MDA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7155547,SCSUD_MEDDF,COUNTRY,TJK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7272860,SCSUD_MEDDF,COUNTRY,SUR,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7204918,SCSUD_MEDDF,COUNTRY,JOR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7282022,SCSUD_MEDDF,COUNTRY,RUS,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7282737,SCSUD_MEDDF,COUNTRY,TKM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7006578,SCSUD_MEDDF,COUNTRY,PAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7017489,SCSUD_MEDDF,COUNTRY,LUX,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7335429,SCSUD_MEDDF,COUNTRY,AND,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7061575,SCSUD_MEDDF,COUNTRY,SLV,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7384001,SCSUD_MEDDF,COUNTRY,HRV,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7220682,SCSUD_MEDDF,COUNTRY,CAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7197845,SCSUD_MEDDF,COUNTRY,IRQ,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7243434,SCSUD_MEDDF,COUNTRY,GRC,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7440961,SCSUD_MEDDF,COUNTRY,KEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7427205,SCSUD_MEDDF,COUNTRY,TJK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7288665,SCSUD_MEDDF,COUNTRY,SMR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7290326,SCSUD_MEDDF,COUNTRY,PRT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7322549,SCSUD_MEDDF,COUNTRY,PRY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7324648,SCSUD_MEDDF,COUNTRY,UGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7361912,SCSUD_MEDDF,COUNTRY,SVN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7425562,SCSUD_MEDDF,COUNTRY,BLR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7433188,SCSUD_MEDDF,COUNTRY,UKR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7260890,SCSUD_MEDDF,COUNTRY,UKR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7261117,SCSUD_MEDDF,COUNTRY,JPN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7264040,SCSUD_MEDDF,COUNTRY,AUS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7264969,SCSUD_MEDDF,COUNTRY,DOM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7271697,SCSUD_MEDDF,COUNTRY,FSM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7278220,SCSUD_MEDDF,COUNTRY,COK,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7312628,SCSUD_MEDDF,COUNTRY,KNA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7379683,SCSUD_MEDDF,COUNTRY,PAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7393853,SCSUD_MEDDF,COUNTRY,TUN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7398252,SCSUD_MEDDF,COUNTRY,MYS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7577768,SCSUD_MEDDF,COUNTRY,COK,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7418108,SCSUD_MEDDF,COUNTRY,HND,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7469071,SCSUD_MEDDF,COUNTRY,FSM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7529445,SCSUD_MEDDF,COUNTRY,VCT,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7529646,SCSUD_MEDDF,COUNTRY,IDN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7544377,SCSUD_MEDDF,COUNTRY,BDI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7544775,SCSUD_MEDDF,COUNTRY,PRT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7622972,SCSUD_MEDDF,COUNTRY,KEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7508157,SCSUD_MEDDF,COUNTRY,HUN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7400887,SCSUD_MEDDF,COUNTRY,TUN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7527647,SCSUD_MEDDF,COUNTRY,SAU,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7555170,SCSUD_MEDDF,COUNTRY,AFG,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7606443,SCSUD_MEDDF,COUNTRY,PAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7564046,SCSUD_MEDDF,COUNTRY,RWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7614605,SCSUD_MEDDF,COUNTRY,IDN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7551446,SCSUD_MEDDF,COUNTRY,NLD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7582800,SCSUD_MEDDF,COUNTRY,GTM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7583927,SCSUD_MEDDF,COUNTRY,NLD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7664191,SCSUD_MEDDF,COUNTRY,GEO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7666134,SCSUD_MEDDF,COUNTRY,HRV,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7550286,SCSUD_MEDDF,COUNTRY,CAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7550839,SCSUD_MEDDF,COUNTRY,TKM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7815732,SCSUD_MEDDF,COUNTRY,PHL,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7697496,SCSUD_MEDDF,COUNTRY,SYC,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7692986,SCSUD_MEDDF,COUNTRY,CHN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7656323,SCSUD_MEDDF,COUNTRY,CAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7742066,SCSUD_MEDDF,COUNTRY,ESP,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7749375,SCSUD_MEDDF,COUNTRY,PNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7864654,SCSUD_MEDDF,COUNTRY,TJK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7753597,SCSUD_MEDDF,COUNTRY,DNK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7708729,SCSUD_MEDDF,COUNTRY,VNM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7805983,SCSUD_MEDDF,COUNTRY,SOM,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7910386,SCSUD_MEDDF,COUNTRY,URY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7812803,SCSUD_MEDDF,COUNTRY,ZWE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7942244,SCSUD_MEDDF,COUNTRY,AGO,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7778620,SCSUD_MEDDF,COUNTRY,BOL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7821920,SCSUD_MEDDF,COUNTRY,DOM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8016935,SCSUD_MEDDF,COUNTRY,KAZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7738610,SCSUD_MEDDF,COUNTRY,BRB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7802882,SCSUD_MEDDF,COUNTRY,OMN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7818993,SCSUD_MEDDF,COUNTRY,GRD,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7676431,SCSUD_MEDDF,COUNTRY,IDN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7731113,SCSUD_MEDDF,COUNTRY,SWZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8095501,SCSUD_MEDDF,COUNTRY,EST,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8111091,SCSUD_MEDDF,COUNTRY,TCD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7682615,SCSUD_MEDDF,COUNTRY,SVK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7847839,SCSUD_MEDDF,COUNTRY,MKD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7848384,SCSUD_MEDDF,COUNTRY,AUS,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7864345,SCSUD_MEDDF,COUNTRY,BRA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7874842,SCSUD_MEDDF,COUNTRY,OMN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8120332,SCSUD_MEDDF,COUNTRY,MDA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8179544,SCSUD_MEDDF,COUNTRY,RUS,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7867567,SCSUD_MEDDF,COUNTRY,BLZ,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8164439,SCSUD_MEDDF,COUNTRY,BHR,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8209762,SCSUD_MEDDF,COUNTRY,MLI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7897251,SCSUD_MEDDF,COUNTRY,GRC,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8220933,SCSUD_MEDDF,COUNTRY,PRT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7965102,SCSUD_MEDDF,COUNTRY,POL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8244452,SCSUD_MEDDF,COUNTRY,SSD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7971891,SCSUD_MEDDF,COUNTRY,RWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8245664,SCSUD_MEDDF,COUNTRY,NPL,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7979875,SCSUD_MEDDF,COUNTRY,SSD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8249994,SCSUD_MEDDF,COUNTRY,GEO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7983566,SCSUD_MEDDF,COUNTRY,NGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7993305,SCSUD_MEDDF,COUNTRY,UKR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8060470,SCSUD_MEDDF,COUNTRY,PAK,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
7994445,SCSUD_MEDDF,COUNTRY,LCA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8026716,SCSUD_MEDDF,COUNTRY,SOM,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8295726,SCSUD_MEDDF,COUNTRY,SVN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8059508,SCSUD_MEDDF,COUNTRY,SWE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8111518,SCSUD_MEDDF,COUNTRY,UGA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8117760,SCSUD_MEDDF,COUNTRY,MDA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8322161,SCSUD_MEDDF,COUNTRY,TUR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,TÃ¼rkiye,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8172428,SCSUD_MEDDF,COUNTRY,SSD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8348092,SCSUD_MEDDF,COUNTRY,KEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8085187,SCSUD_MEDDF,COUNTRY,IDN,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8366137,SCSUD_MEDDF,COUNTRY,POL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8369408,SCSUD_MEDDF,COUNTRY,ISL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8249409,SCSUD_MEDDF,COUNTRY,MNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8275072,SCSUD_MEDDF,COUNTRY,RUS,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8464635,SCSUD_MEDDF,COUNTRY,CUB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8394357,SCSUD_MEDDF,COUNTRY,AUT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8492812,SCSUD_MEDDF,COUNTRY,LVA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8281513,SCSUD_MEDDF,COUNTRY,ATG,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8296385,SCSUD_MEDDF,COUNTRY,CRI,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8406451,SCSUD_MEDDF,COUNTRY,CRI,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8299328,SCSUD_MEDDF,COUNTRY,SEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8231214,SCSUD_MEDDF,COUNTRY,LTU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8542105,SCSUD_MEDDF,COUNTRY,IRN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8553764,SCSUD_MEDDF,COUNTRY,COK,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8233014,SCSUD_MEDDF,COUNTRY,ARM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8408737,SCSUD_MEDDF,COUNTRY,TON,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8410309,SCSUD_MEDDF,COUNTRY,COD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8443135,SCSUD_MEDDF,COUNTRY,SLE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8443897,SCSUD_MEDDF,COUNTRY,JAM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8244878,SCSUD_MEDDF,COUNTRY,HRV,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8653701,SCSUD_MEDDF,COUNTRY,PNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8456481,SCSUD_MEDDF,COUNTRY,KNA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8456710,SCSUD_MEDDF,COUNTRY,VUT,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8464254,SCSUD_MEDDF,COUNTRY,BLZ,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8465518,SCSUD_MEDDF,COUNTRY,TON,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8490340,SCSUD_MEDDF,COUNTRY,ISL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8504013,SCSUD_MEDDF,COUNTRY,COL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8508640,SCSUD_MEDDF,COUNTRY,LKA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8738352,SCSUD_MEDDF,COUNTRY,RWA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8619101,SCSUD_MEDDF,COUNTRY,DOM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8606287,SCSUD_MEDDF,COUNTRY,NPL,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8809684,SCSUD_MEDDF,COUNTRY,TZA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8675893,SCSUD_MEDDF,COUNTRY,IRQ,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8635508,SCSUD_MEDDF,COUNTRY,BGD,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8642301,SCSUD_MEDDF,COUNTRY,PAK,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8576179,SCSUD_MEDDF,COUNTRY,SRB,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8654660,SCSUD_MEDDF,COUNTRY,IRN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8668762,SCSUD_MEDDF,COUNTRY,BGD,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8668847,SCSUD_MEDDF,COUNTRY,ROU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8819666,SCSUD_MEDDF,COUNTRY,AFG,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8912515,SCSUD_MEDDF,COUNTRY,LUX,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8698906,SCSUD_MEDDF,COUNTRY,NIC,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8707116,SCSUD_MEDDF,COUNTRY,SLE,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8707693,SCSUD_MEDDF,COUNTRY,VNM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8712295,SCSUD_MEDDF,COUNTRY,CAN,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8735784,SCSUD_MEDDF,COUNTRY,FIN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8964692,SCSUD_MEDDF,COUNTRY,PER,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8767878,SCSUD_MEDDF,COUNTRY,KAZ,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8853229,SCSUD_MEDDF,COUNTRY,ZAF,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8854768,SCSUD_MEDDF,COUNTRY,HUN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8855484,SCSUD_MEDDF,COUNTRY,PRT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8865085,SCSUD_MEDDF,COUNTRY,AZE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8593283,SCSUD_MEDDF,COUNTRY,AFG,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9014017,SCSUD_MEDDF,COUNTRY,TKM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9038989,SCSUD_MEDDF,COUNTRY,AGO,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9050922,SCSUD_MEDDF,COUNTRY,GUY,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8879635,SCSUD_MEDDF,COUNTRY,LKA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8920650,SCSUD_MEDDF,COUNTRY,TCD,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8924881,SCSUD_MEDDF,COUNTRY,BFA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8956290,SCSUD_MEDDF,COUNTRY,GTM,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8975037,SCSUD_MEDDF,COUNTRY,NOR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9249625,SCSUD_MEDDF,COUNTRY,NIC,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9002608,SCSUD_MEDDF,COUNTRY,MCO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9265661,SCSUD_MEDDF,COUNTRY,ROU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9095200,SCSUD_MEDDF,COUNTRY,SVN,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8881888,SCSUD_MEDDF,COUNTRY,IND,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8897795,SCSUD_MEDDF,COUNTRY,DEU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8955090,SCSUD_MEDDF,COUNTRY,GHA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9102164,SCSUD_MEDDF,COUNTRY,ARM,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9110283,SCSUD_MEDDF,COUNTRY,EST,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9341583,SCSUD_MEDDF,COUNTRY,MLT,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9280992,SCSUD_MEDDF,COUNTRY,SDN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9159844,SCSUD_MEDDF,COUNTRY,SGP,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9290666,SCSUD_MEDDF,COUNTRY,TZA,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8891439,SCSUD_MEDDF,COUNTRY,UKR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9291635,SCSUD_MEDDF,COUNTRY,MNG,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9484687,SCSUD_MEDDF,COUNTRY,CIV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9185024,SCSUD_MEDDF,COUNTRY,THA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9197935,SCSUD_MEDDF,COUNTRY,VCT,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9238251,SCSUD_MEDDF,COUNTRY,SVK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9252979,SCSUD_MEDDF,COUNTRY,BDI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
8995109,SCSUD_MEDDF,COUNTRY,BOL,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9267720,SCSUD_MEDDF,COUNTRY,CUB,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9405839,SCSUD_MEDDF,COUNTRY,CHE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9325465,SCSUD_MEDDF,COUNTRY,BGD,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9331010,SCSUD_MEDDF,COUNTRY,BDI,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9369638,SCSUD_MEDDF,COUNTRY,SLV,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9601177,SCSUD_MEDDF,COUNTRY,LTU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9455997,SCSUD_MEDDF,COUNTRY,SWE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9463281,SCSUD_MEDDF,COUNTRY,KEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9491615,SCSUD_MEDDF,COUNTRY,IRL,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9658714,SCSUD_MEDDF,COUNTRY,TUN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9335904,SCSUD_MEDDF,COUNTRY,THA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9454219,SCSUD_MEDDF,COUNTRY,NLD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9457605,SCSUD_MEDDF,COUNTRY,ZMB,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9493822,SCSUD_MEDDF,COUNTRY,AGO,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9534921,SCSUD_MEDDF,COUNTRY,RUS,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9613157,SCSUD_MEDDF,COUNTRY,AFG,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9578245,SCSUD_MEDDF,COUNTRY,NLD,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9614876,SCSUD_MEDDF,COUNTRY,DNK,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9740952,SCSUD_MEDDF,COUNTRY,GEO,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9586511,SCSUD_MEDDF,COUNTRY,THA,SEAR,YEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9684271,SCSUD_MEDDF,COUNTRY,FRA,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
863853,SCSUD_MEDDF,COUNTRY,ATG,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9506140,SCSUD_MEDDF,COUNTRY,IRN,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9588211,SCSUD_MEDDF,COUNTRY,CPV,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9524730,SCSUD_MEDDF,COUNTRY,CHE,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9666605,SCSUD_MEDDF,COUNTRY,MOZ,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9684974,SCSUD_MEDDF,COUNTRY,KEN,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9735775,SCSUD_MEDDF,COUNTRY,DEU,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9745114,SCSUD_MEDDF,COUNTRY,PAK,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
737643,SCSUD_MEDDF,COUNTRY,CHN,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9704944,SCSUD_MEDDF,COUNTRY,BLR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9739283,SCSUD_MEDDF,COUNTRY,KOR,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9747537,SCSUD_MEDDF,COUNTRY,COG,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9755661,SCSUD_MEDDF,COUNTRY,MEX,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9710500,SCSUD_MEDDF,COUNTRY,PAK,EMR,YEAR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9711427,SCSUD_MEDDF,COUNTRY,SYC,AFR,YEAR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naloxone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9752501,SCSUD_MEDDF,COUNTRY,KHM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9762979,SCSUD_MEDDF,COUNTRY,VNM,WPR,YEAR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
9704592,SCSUD_MEDDF,COUNTRY,BRA,AMR,YEAR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_drugform_buprenorphine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
19494,SCSUD_MEDDF,COUNTRY,GBR,EUR,YEAR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_incl_natdrugform_buprenorphinenaloxone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine included in drug formulary",EN,Service coverage for substance use disorders survey
